Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of Goserelin 1M Implant Hexal vs reference in advanced prostate cancer
2004-000808-40Phase 3Completed
- Sponsor
- Hexal AG
- Start
- Nov 2004
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of goserelin in prostate cancer (PCa) (2 arms), sponsored by Hexal AG. Primary endpoint: Testosterone suppression success rate. Started Nov 2004; status: completed.
02
Drugs
goserelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2004-000808-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000808-40.